Varicella vaccination in Japan, South Korea, and Europe. by Sadzot-Delvaux, Catherine et al.
Varicella Vaccination outside the United States • JID 2008:197 (Suppl 2) • S185
S U P P L E M E N T A R T I C L E
Varicella Vaccination in Japan, South Korea,
and Europe
Catherine Sadzot-Delvaux,1 Bernard Rentier,1 Peter Wutzler,2 Yoshizo Asano,3 Sadao Suga,3 Tetsushi Yoshikawa,3
and Stanley A. Plotkin4
1Unit of Fundamental Virology and Immunology, Department of Life Sciences, University of Liege, Sart Tilman, Belgium; 2Universita¨tsklinikum
Jena, Institut fu¨r Virologie und Antivirale Therapie, Jena, Germany; 3Department of Pediatrics, Fujita Health University School of Medicine,
Toyoake, Japan; 4Sanofi Pasteur, Doylestown, and University of Pennsylvania, Philadelphia, Pennsylvania
The most extensive use of varicella vaccine has been in the United States and Canada, where it is universally
recommended. However, a number of other countries now have recommendations for use of the vaccine,
which has been expanding in Europe and Latin America. In this article, we review information concerning
varicella vaccination in Japan, where the vaccine was first developed, and in South Korea and parts of Europe.
Despite the worldwide availability of an efficient vaccine, varicella vaccination policy is highly variable from
country to country. The recent development of a tetravalent vaccine against measles, mumps, rubella, and
varicella could modify this variability in the future. It is evident that efforts to control varicella will spread
gradually to all continents.
Although varicella vaccine has been used for the uni-
versal vaccination (UV) of children in the United States
since 1995, other countries have been slow to adopt it
until recently. Even Japan, where the vaccine was de-
veloped, is far from universal immunization against
varicella. Nevertheless, the use of varicella vaccine is
accelerating, and, in this article, we review the policies
in Japan, South Korea, and parts of Eastern andWestern
Europe.
JAPAN AND SOUTH KOREA
Takahashi et al. [1] developed a live attenuated varicella
vaccine in Japan in 1974, using the Oka strain of var-
icella-zoster virus (VZV). The vaccine was well toler-
ated, immunogenic, and efficacious in both healthy and
high-risk children in extensive clinical trials [2, 3]. In
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Japan, varicella vaccine is produced by the Research
Foundation for Microbial Diseases (called “Biken” in
Japan) at Osaka University, Osaka. Since 1987, the vac-
cine has been recommended for use in susceptible per-
sons at !12 months of age. In addition, it is recom-
mended for patients with acute leukemia, malignant
tumors, nephrotic syndrome, and asthma when they
are in remission and not severely immunosuppressed.
Vaccination of health care workers who are susceptible
is particularly recommended, as is vaccination of sus-
ceptible adults, individuals in closed communities, and
siblings of immunosuppressed individuals. Contrain-
dications to vaccination include acute febrile illness,
pregnancy, and a history of anaphylaxis to vaccine com-
ponents. Because varicella vaccination is not compul-
sory, coverage among infants has increased only from
6.8% at introduction in 1987 to 32.1% in 2005.
The low level of vaccine coverage among Japanese
infants will not alter the circulation of wild-type VZV,
and the epidemiology of natural varicella has not
changed greatly since the introduction of the vaccine
[4]. In the future, if the rate of vaccine coverage in-
creases owing to the introduction of a compulsory im-
munization schedule, vaccine recipients will have a re-
duced risk of being exposed to VZV and, thus, reduced
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United States [9]a 1600 !4 … 4.1 …
Belgium [10, 11] 1200 … 93 (10) 3.4 0.8
France [12] 925 4 … 3.5 3.3
Germany [13–16] 915 … 94.2 (10–11) 6.7 0.7b
Italy [17] 200 4.5 82.1 (10–14) 0.18 …
Spain [18] 910 15 90 (10–11) 2.7 3.7
The Netherlands [19] 254 … 197.5 (10–14) 1.3 2
United Kingdom [20] 1291 … 95 (15) 4.5 4c
a Data are for the period before the start of the varicella vaccination program in 1995.
b Among patients !17 years of age.
c Among patients !25 years of age.
boosting of immunity via natural means. It is expected that a
second vaccine dose will be required for maintaining protective
immunity against natural disease.
The overall safety of the Biken vaccine has been good. How-
ever, in 1994, immediate anaphylactic or allergic reactions after
many vaccinations became a big problem in Japan [5]. These
reactions were associated with the use of gelatin as the stabilizer
in the vaccine. Gelatin-free varicella vaccine was introduced in
1999, which resulted in a decrease in local reactions and skin
rashes between days 0 and 2 after vaccination [6]. Antibody
responses after immunization with gelatin-free vaccine, eval-
uated by immune-adherence hemagglutination assay and by
ELISA using lectin affinity chromatography–purified glycopro-
teins from VZV, were similar to those after immunization with
the previous, gelatin-containing vaccine [6].
Varicella vaccine has been distributed in South Korea since
1988. It was imported until 1993, when local manufacture be-
gan. There are no reliable statistics on vaccine coverage in South
Korea, but the combined production volume is 1500,000 doses
annually, which is larger than the annual birth cohort of
∼400,000. Since January 2005, varicella vaccination of children
12–15 months of age has been added to the national immu-
nization recommendations, and, in July 2005, varicella became
a designated (category II) infectious disease.
EUROPE
Varicella vaccination is not yet routine throughout Europe [7].
Each European country has its own health department and
therefore its own health policy. Although the Oka strain–based
vaccine (produced in Europe by Merck and GlaxoSmithKline)
has been licensed in most countries, UV programs against var-
icella have been implemented only in Germany and Sicily.Other
European countries remain reluctant to implement UV and
recommend only vaccination targeted at certain high-risk
groups, such as health care workers. This situation probably
will be reconsidered with the commercialization of the tetra-
valent measles-mumps-rubella (MMR) with varicella (MMRV)
vaccine (ProQuad by Merck and Priorix-Tetra by Glaxo-
SmithKline).
Epidemiology of varicella. Varicella usually is not a re-
portable disease in Europe, so an accurate estimate of disease
burden is difficult to determine. The number of varicella cases
could be underestimated significantly in some countries, as
documented in Italy by Ciofi degli Atti et al. [8]. However, the
epidemiology of varicella appears to be similar across Europe
and even is similar to that in the prevaccine era in the United
States (table 1) [9]. In both the United States and Europe, most
people are infected before adolescence. Seroprevalence reaches
!90% by 10 years of age, and varicella incidence is ∼13–16
cases/1000 people/year [9]. In most European countries, the
highest incidence is observed among children 4–5 years of age,
but more-complete and -standardized epidemiological studies
are needed.
Economic burden. Several European studies have evaluated
the impact of varicella vaccination, taking into account the
direct as well as indirect costs of the disease [21]. However,
economic structures and health policies vary quite considerably
in Europe. In some countries where vaccination is free of
charge, resources are not available for new vaccines. In coun-
tries where parents pay for vaccines, high coverage is difficult
to attain. Although direct health care costs usually are sup-
ported by health departments, indirect costs, such as parents’
work loss, are not. Thus, UV often fails to appear cost-effective
when considered by health departments, even though it would
be cost-effective from a societal perspective.
Vaccination policies. In 2004, the European Working
Group on Varicella (Eurovar), created in 1998 to address var-
icella vaccination issues in Europe, published a consensus state-
ment recommending “routine varicella vaccination for all
healthy children between 12 and 18 months and to all suscep-
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Table 2. Varicella vaccination status and recommendations in European countries.
Country UV Vaccination status and/or recommendation(s)
Austria No Recommended for high-risk groups: seronegative women of childbearing age; seronegative health care work-
ers, teachers, or day care personnel; immunosuppressed children (upcoming chemotherapy or transplanta-
tion [administered before transplantation]); and seronegative family members of children at high risk
Belgium No On an individual, named-patient basis (vaccination not reimbursed): 1 dose for healthy children (1–24 months
of age) or 2 doses (4–8 weeks apart) for older individuals
Recommended for high-risk groups: seronegative women of childbearing age, seronegative susceptible ado-
lescents and young adults, seronegative health care workers or persons with close contact with children,
and seronegative family members of children at high risk
Cyprus No None
Czech Republic No Recommended for populations at high risk for complications
Estonia No Not yet recommended
Finland No On an individual, named-patient basis
France No Recommended for high-risk groups: seronegative medical students, paramedical students, health care work-
ers, and persons with frequent contact with children; seronegative family members of immunosuppressed
patients; and adults (118 years of age) without previous VZV infection, after exposure
Germany Yes Recommended as part of the childhood vaccination schedule: 1 dose, at 11–14 months of age; 2 doses, at
15–23 months of age (if MMRV vaccine is administered)
Recommended as catch-up vaccination for individuals "17 years of age who do not have a history of varicella
Recommended for the following seronegative individuals: staff in medical services and newly hired staff at
facilities for preschool children, women attempting pregnancy, patients with severe neurodermatitis, pa-
tients with upcoming immunosuppressive therapy or organ transplantation, and susceptible persons in
close contact with the above-mentioned groups
Greece No Routine vaccination recommended for healthy children 12–18 months of age and for susceptible children; not
yet endorsed by the Ministry of Health
Hungary No On an individual, named-patient basis
Italy Yes Recommended to all susceptible adolescents and adults
Recommended for universal pediatric vaccination if the region can ensure 180% coverage after 1 yeara
Latvia No Recommended for children in accordance with indications in the vaccine’s instructions for use and for sus-
ceptible adults
Lithuania (Yes) Recommendation for universal pediatric vaccination but not yet part of the vaccination schedule
Malta No Considering introduction of recommendations for childhood immunization, to be administered with the first
dose of MMR vaccine
Poland No Recommended for susceptible children and adults and for patients with leukemia
Slovak Republic No Recommended for high-risk groups
Slovenia No Recommended for children in remission from acute leukemia, patients who need high doses of
corticosteroids, health care workers, and healthy children if parents demand
Sweden No Recommended for high-risk groups and for seronegative healthy children 112 years of age and adults who
have not had varicella
United Kingdom No Recommended for nonimmune health care workers and healthy close contacts of immunosuppressed
patients
On an individual, named-patient basis
NOTE. MMR, measles-mumps-rubella; MMRV, measles-mumps-rubella-varicella; UV, universal vaccination.
a So far, Sicily is the only region that has implemented this UV program.
tible children before their 13th birthday, in addition to catch-
up vaccination in older children and adults without a reliable
history of varicella and who are at risk of transmission and
exposure” [22, p. 385]. The experts insisted that this policy
should be recommended only if a very high coverage rate can
be effectively achieved, to avoid any age shift in the epidemi-
ology of chickenpox toward older children and adults [22].
This recommendation was in complete agreement with rec-
ommendations published by the World Health Organization
(WHO) in 2003 [23].
Varicella vaccine has since been licensed in most European
countries, but UV has been implemented in only Germany and
Sicily. In Sicily, the vaccine is administered in the second year
of life, and a catch-up vaccine is given at 12 years of age to
those with no history of varicella. The situation in Germany is
described in the subsection below. Elsewhere in Europe, policy
varies from country to country (table 2). In general, vaccination
is recommended for high-risk populations, such as health care
workers, nonimmune adults, and nonimmune persons living
with immunocompromised individuals. Since MMR vaccina-
tion is included in all European vaccine schedules and since
good coverage usually is reached, varicella vaccination may be
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regarded more favorably once the tetravalent MMRV vaccine
is licensed. The experience in the United States suggests that
optimal protection against VZV infection would be obtained
best if 2 doses of varicella vaccine are given in early childhood.
If a 2-dose schedule is adopted in Europe, it would be consid-
ered important to harmonize the doses with existing MMR
schedules.
Concerns about UV. The European countries that have not
yet recommended UV have various arguments for rejecting it.
They mostly have yet to be convinced of the significance of the
disease burden and of the cost-effectiveness of the vaccine, the
duration of protection, and the impact of childhood vaccina-
tion on herpes zoster (HZ) epidemiology, since the theoretic
possibility exists that decreased circulation of wild-type virus
resulting fromwidespread vaccinationwill reduce opportunities
for natural boosting of the immune response in the elderly and,
therefore, will lead to an increase in cases of HZ. The economic
issues discussed earlier are certainly a major barrier to the in-
troduction of varicella vaccination in some countries.
Germany. Germany was the first European country to rec-
ommend UV against varicella. The vaccine was licensed in 1984
for use with patients at high risk for severe varicella, such as
seronegative patients with acute leukemia, and their close con-
tacts, as well as with health care workers in special hospitals.
In 1994, when a vaccine formulation became available that
could be stored in a refrigerator between 2"C and 8"C, the
Standing Committee on Vaccinations (STIKO) at the Robert
Koch Institute, Berlin (a German federal institution responsible
for disease control and prevention), extended the recommen-
dations to include healthy children "6 years of age and to
seronegative women of childbearing age. Four years later, the
recommendations were widened to include susceptible adoles-
cents and adults. However, only a small number of individuals
were vaccinated. In 2001, on the basis of seroprevalence data
showing immunity gaps among adolescents [13], vaccination
of adolescents 12–15 years of age who did not have a history
of varicella was recommended [24]. The number of vaccinated
individuals increased but still remained low. In 2001, STIKO
also recommended that vaccination after exposure should be
considered for persons without a history of varicella who were
at risk for severe varicella, if the vaccine could be administered
within 5 days of exposure or within 3 days after onset of lesions
in the index case [24].
In July 2004, STIKO recommended UV, on the basis of evi-
dence from epidemiological studies showing a continuing high
disease burden of varicella among young children [14, 25] and
of modeling that favored vaccination of all infants rather than
the adolescent-vaccination strategy [15, 26], together with the
success of the varicella vaccination program in the United States
[27, 28]. Vaccination was scheduled for infants 11–14 months
of age, preferably at the same time as administration of the
MMR vaccine. Catch-up vaccination for other children and
adolescents was recommended, particularly for persons 9–17
years of age who did not have a history of varicella [29]. Sus-
ceptible individuals 113 years of age had to receive 2 doses
administered at least 4 weeks apart. Previous targeted indica-
tions also were retained (table 2). However, the indication for
children with leukemia is currently being deleted because of
the danger of vaccine complications.
The German childhood vaccination schedule implemented
in July 2006 [30] recommends use of the tetravalent combi-
nation MMRV vaccine for infants and children. This MMRV
formulation should be administered in a 2-dose regimen to all
children (table 2). The second dose of MMRV vaccine should
reduce the number of vaccinees with primary vaccine failure
and should improve vaccine uptake. Monovalent varicella vac-
cines are to be used as before.
The implementation of UV in Germany was aimed mainly
at reducing the high numbers of VZV infections, estimated at
750,000 cases/year [31]. Data on complications, hospitalization
rates, and costs incurred by varicella also contributed to the
rationale for implementing UV [14, 15]. Furthermore, the de-
cision to implement UV was stimulated by the expectation that
herd immunity would protect susceptible infants, young chil-
dren, pregnant women, and immuncompromised individuals
not eligible for vaccination from severe varicella. As with most
other vaccinations recommended by STIKO, statutory health
insurance covers the costs of UV. The number of vaccine doses
sold increased in proportion to the degree that the statutory
health insurance funds were paying for varicella vaccination.
Sales figures for varicella vaccine rose from 27,000 doses in
2003 to 406,000 doses in 2005, and sales of 565,000 doses were
estimated in 2006 (Intercontinental Marketing Services Health,
Inc., unpublished data). Thus, it can be estimated that half of
the birth cohort in 2006 was vaccinated. Increasing compliance
with varicella vaccination can be expected if the combination
MMRV vaccine is used. In 2004, coverage rates at school entry
for the MMR vaccine were 93.3% for the first dose but only
67.7% for the second dose [32]. Therefore, much effort will
be necessary to enhance vaccine uptake.
Varicella is not a notifiable disease in Germany. In 2005, a
countrywide varicella sentinel surveillance network was initi-
ated by the working group for measles and varicella, to collect
valid epidemiological data for monitoring the implementation
of the immunization program and its impact on disease epi-
demiology. This working group is a joint initiative of the Robert
Koch Institute and the vaccine manufacturers. Data on fre-
quency and distribution of varicella and HZ, the frequency of
breakthrough disease, and the number of vaccine doses ad-
ministered are generated by monthly sentinel questionnaires
[32].
Eastern European countries. In Eastern Europe, the ca-
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pacity for funding national vaccination programs is limited
(table 2). Thus, UV is in fact recommended in Lithuania, but
it cannot be incorporated into the national childhood immu-
nization schedule because the vaccine is not funded by the state.
Consequently, the vaccine is rarely administered.
The vaccine was registered in Latvia in 1997, but only 100
persons (of which 72 are !18 years of age) were vaccinated in
2005, owing to the high cost. Nevertheless, Latvian health au-
thorities are discussing the introduction of infant varicella vac-
cination into the national vaccination schedule in 2008. In
Estonia, the first varicella vaccine was registered in 1999, but
it is not yet recommended officially.
Slovenia will reconsider a vaccination program when the
MMRV vaccine is available. In the Czech Republic, there is
ongoing discussion among clinicians and epidemiologists re-
garding the possibility of including the varicella vaccine in the
general vaccination scheme, because the economic impact of
the disease from loss of earnings by parents caring for children
becomes a social problem in some instances. In the Slovak
Republic, licensure of varicella vaccine was approved in 2007
for use with high-risk populations. In Poland, varicella vacci-
nation is recommended only for high-risk groups and is pub-
licly funded for these persons. In Hungary, the vaccine can be
obtained for use on a case-by-case basis, in accordance with
the manufacturer’s instructions.
DISCUSSION
The type of varicella vaccine available worldwide contains the
Oka strain of live attenuated VZV and was developed originally
by Takahashi et al. [1] in Japan in 1974. Although Japan (in
1987) and South Korea (in 1988) were the first countries to
license the vaccine and although 110 years have elapsed since
the United States commenced successful UV of children, other
countries have been slow to consider their varicella disease
burden and to develop policies for use of the vaccine. Although
the vaccine continues to be underutilized in Japan, countries
such as South Korea, Canada, Brazil, Uruguay, Qatar, Taiwan,
and Australia have adopted UV, as have Germany and Sicily.
Some other European countries appear to be likely to do so
once the combined MMRV vaccine is available to them. Other
countries in Europe and elsewhere will be constrained by the
vaccine’s cost and most likely will be guided by the WHO
recommendations published in 2003 [23], which state that
“routine childhood immunization against varicella may be con-
sidered in countries where this disease is a relatively important
public health and socioeconomic problem, where the vaccine
is affordable, and where high (85%–90%) and sustained vaccine
coverage can be achieved…the vaccine may be offered in any
country to individual adolescents and adults without a history
of varicella, in particular to those at increased risk of contracting
or spreading the infection.”
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